Abstract:Vascular complications are the major causes of death in patients with diabetes, and endothelial dysfunction is the earliest event in vascular complications of diabetes. It has been reported that plasma irisin level is significantly reduced in patients with type 2 diabetic patients. The present study aimed to investigate whether irisin improved endothelial function in type 2 diabetes as well as the underlying mechanisms. The type 2 diabetes model was established by feeding C57BL/6 mice with high-fat diet. The type 2 diabetic mice exhibited reduced serum irisin level and impaired endothelial function. Irisin treatment (0.5mg/kg/d) for two weeks improved vascular function based on the evaluation of endothelium-dependent vasorelaxation and p-VASP levels. To investigate the direct endothelial protective effects of irisin, diabetic aortic segments were incubated with irisin (1μg/ml) ex vivo. Exposure to irisin improved endothelium-dependent vasorelaxation of diabetic aortas. Mechanically, the diabetic aortic segments exhibited increased oxidative/nitrative stresses. Irisin reduced the diabetes-induced oxidative/nitrative stresses evidenced by reducing overproduction of superoxide and peroxynitrite, and down-regulation of iNOS and gp91phox. To further investigate the protective effects of irisin on endothelial cells and the underlying mechanisms, human umbilical vein endothelial cells (HUVECs) cultured in high-glucose/high-fat (HG/HF) medium were pre-incubated with irisin. Irisin (1μg/ml) reduced the oxidative/nitrative stresses and apoptosis induced by HG/HF in HUVECs probably via inhibiting activation of PKC-β/NADPH oxidase and NF-κB/iNOS pathways. Taken together, irisin alleviates endothelial dysfunction in type 2 diabetes partially via reducing oxidative/nitrative stresses through inhibiting signaling pathways implicating PKC-β/NADPH oxidase and NF-κB/iNOS, suggesting that irisin may be a promising molecule for the treatment of vascular complications of diabetes.

New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases

Irisin Reverses Insulin Resistance in C2C12 Cells Via the P38-Mapk-pgc-1α Pathway.

Irisin Improves Endothelial Function in Type 2 Diabetes Through Reducing Oxidative/nitrative Stresses

Irisin inhibits high glucose-induced endothelial-to-mesenchymal transition and exerts a dose-dependent bidirectional effect on diabetic cardiomyopathy.

Irisin Improves Fatty Acid Oxidation and Glucose Utilization in Type 2 Diabetes by Regulating the AMPK Signaling Pathway.

Irisin: a new molecular marker and target in metabolic disorder

Irisin a Novel Metabolic Biomarker: Present Knowledge and Future Directions

The Controversial Role of Irisin in Clinical Management of Coronary Heart Disease

Irisin Attenuates Myocardial Ischemia/Reperfusion Injury and Improves Mitochondrial Function Through AMPK Pathway in Diabetic Mice

Antiarrhythmic potentials of irisin in ischemia/reperfusion injury of diabetic rats through modulating mitochondria-endoplasmic reticulum interaction and inhibiting pyroptosis

Irisin in atherosclerosis

Irisin ameliorates high glucose‐induced cardiomyocytes injury via AMPK/mTOR signal pathway

Irisin ameliorates diabetic kidney disease by restoring autophagy in podocytes.

Irisin, an Exercise‐induced Myokine As a Metabolic Regulator: an Updated Narrative Review

Irisin Improves Insulin Resistance by Inhibiting Autophagy Through the PI3K/Akt Pathway in H9c2 Cells.

Irisin Promotes Human Umbilical Vein Endothelial Cell Proliferation Through the ERK Signaling Pathway and Partly Suppresses High Glucose-Induced Apoptosis

GW28-e0562 Irisin Deficiency Disrupts Glucose Utilization and Sensitizes the Heart to Ischemia/Reperfusion Injury

Potential role of irisin in digestive system diseases

Irisin alleviates high glucose-induced hypertrophy in H9c2 cardiomyoblasts by inhibiting endoplasmic reticulum stress

Irisin, an exercise-induced bioactive peptide beneficial for health promotion during aging process